Home List your patent My account Help Support us

MUCOSAL VACCINE FOR PORCINE CIRCOVIRUS TYPE 2

[Category : - OTHER- HEALTH]
[Viewed 1050 times]

The invention relates to a vaccine, preferably administered via mucous membranes, for controlling diseases caused by infectious agents that use heparan sulphate (HS) as a cell receptor. The vaccine consists of an immunogenic formulation for veterinary use, which comprises an antigen of which the cell receptor is heparan sulphate (HS), and a vehicle of oral, intranasal or parenteral administration. The vehicle is biopolymers of D-glucosamine and N-acetyl-D-glucosamine functionalised with sulphur atoms, and/or a biopolymer of chitosan functionalised with sulphur atoms; and the antigen is microencapsulated by said types of functionalised biopolymers. rnVaccine of preferential administration via mucous membranes, for the control of diseases generated by agents or infectious agents that use heparan sulfate (HS) as a cellular receptor, consisting of an immunogenic formulation for veterinary use and comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration. The vaccine is based on particles similar to PCV2 virus (PSV) derived from yeast and microencapsulated with chitosan. Evidence suggests it might also be useful for other heparin-sulfate receptor disease pathogens across multiple livestock, aquaculture, and companion animal species.rnThis technology has reached pre-clinical trials in mice and pigs in relevant environments and with some controlled variables in order to optimize the chitosan formulation of the vaccine.rnCurrently, a commercially available mucosal vaccine against PCV doesn´t exist. rnThere is no combined vaccine against PCV2 and M. Hyopneumoniae in Chile and the Latin American market available, too.rnAn oral formulation may generate a stronger protective mucosal-generated immunity against PCV diseases.rnThe chitosan sulphate presents structural similarity with the HS cell receptor; therefore, this biopolymer can generate a specific binding effect against CRP-associated antigens that use this receptor, which is expected to facilitate the design of more effective vaccines against CRP with regard to microencapsulation and controlled delivery.rn

Financial information

In 2017, the porcine vaccine segment is expected to account for the largest share of the global veterinary vaccines market, in terms of value.
The North America porcine vaccine market is highly fragmented owing to the presence of numerous large and small players. Zoetis, Inc., Merial Animal Health, Merck Animal Health, and Elanco Animal Health are the top four players that accounted for around 74.0% of entire market. Three out of the top four animal health companies are already engaged in the PCVD market with their own injectable vaccine technology. Nevertheless, a new and highly effective vaccine technology may disrupt their market.

WE ARE INTERESTED IN SEARCHING FOR LICENSING OPPORTUNITIES OR PARTNERS WHO SUPPORT US TO BRING THIS TECHNOLOGY TO A FURTHER DEVELOPMENT STATE THROUGH MUTUALLY BENEFICIAL COLLABORATION AGREEMENTS

Patent publications:

EP 3372240

Asking price:

Make an offer

Rate this patent

Great invention
Viewed: 1050 times

Seller:

knowhubchile (Chile)

Seller's website

Ask a question
or start a negotiation

Contact the seller

Share on social media